Private dermatology providers rely on DERM to assess patients with suspicious moles and skin lesions for possible skin cancer – allowing rapid prioritisation of high risk cases and unlocking greater value from your patient waiting list.
Demand for skin cancer diagnosis is rising rapidly across Europe. High cost specialist capacity is currently required to assess and triaging all lesions, driving up costs of treatment for benign and low complexity cases, while delaying care for patients at higher-risk, where earlier intervention supports better patient outcomes and greater clinic revenue.
30 year increase in global melanoma incidence
of patients presenting are confirmed as malignant
Our AI as a Medical Device – DERM – analyses dermoscopic images of moles and skin lesions for 11 of the most common benign, pre-malignant and malignant lesion types – including high-risk cancers.
As the only AI approved to make clinical decisions in the management of skin cancer, DERM rapidly prioritises high value and complex cases for specialist review, while safely deprioritising or discharging patients with benign lesions.
Lesions assessed by DERM as high-risk/malignant are:
more likely to have a confirmed cancer diagnosis
more likely to be sent for biopsy/excision
Hospitals
As the only Class III CE-marked AI as a Medical Device for skin cancer, DERM is able to reduce time spent on initial assessment of skin lesions, and increase the number of patients staff can see and treated.
If you would like to know more about how Skin Analytics can help you and your dermatology team deliver best in class dermatology, get in touch.